BIAF Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
1.5M
+11.8%
1.4M
-15.1%
1.6M
+10.1%
1.4M
+13.9%
1.3M
Cost of Revenue
0
0
-100.0%
900.1K
-4.5%
942.2K
0
Gross Profit
1.5M
+11.8%
1.4M
+95.1%
692.7K
+37.5%
503.9K
-60.3%
1.3M
Operating Expenses
4.8M
-2.5%
5.0M
+29.7%
3.8M
+36.9%
2.8M
-26.1%
3.8M
R&D
837.5K
+22.5%
683.7K
+2.2%
668.8K
+41.1%
473.9K
+7.5%
440.7K
SG&A
2.9M
-11.8%
3.2M
+6.7%
3.0M
+37.5%
2.2M
-0.2%
2.2M
Operating Income
-3334864
+7.8%
-3616976
-15.3%
-3136963
-36.8%
-2292846
+8.9%
-2515560
EBITDA
-3273308
+6.5%
-3502458
-16.2%
-3013304
-38.3%
-2179486
+9.3%
-2402331
Net Income
-3366082
+7.3%
-3630610
-15.7%
-3137466
+37.9%
-5051084
-24.4%
-4060787
EPS (Basic)
$-9.60
+21.0%
$-12.15
$-71.10
+6.5%
$-76.05
EPS (Diluted)
$-9.60
+21.0%
$-12.15
$-71.10
+6.5%
$-76.05
Shares (Diluted)
348.5K
+16.3%
299.7K
71.1K
+33.2%
53.4K
bioAffinity Technologies (BIAF) — Financials